Plus Therapeutics (NASDAQ:PSTV) Issues Earnings Results, Misses Estimates By $0.16 EPS

Plus Therapeutics (NASDAQ:PSTV) issued its earnings results on Thursday. The company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.16), Zacks reports. The business had revenue of $1.80 million for the quarter, compared to analysts’ expectations of $1.19 million.

Plus Therapeutics Stock Performance

Shares of PSTV stock traded down $0.35 on Friday, hitting $1.17. The company had a trading volume of 2,457,898 shares, compared to its average volume of 3,921,736. Plus Therapeutics has a twelve month low of $0.24 and a twelve month high of $2.67. The firm has a market cap of $6.90 million, a P/E ratio of -0.46 and a beta of 0.73. The stock’s 50-day moving average is $1.11 and its two-hundred day moving average is $1.24.

Analysts Set New Price Targets

A number of brokerages have issued reports on PSTV. HC Wainwright lowered their target price on Plus Therapeutics from $8.00 to $5.50 and set a “buy” rating for the company in a report on Friday. Ascendiant Capital Markets dropped their price objective on shares of Plus Therapeutics from $20.00 to $19.00 and set a “buy” rating for the company in a report on Monday, December 9th. Finally, D. Boral Capital reissued a “buy” rating and set a $9.00 target price on shares of Plus Therapeutics in a report on Friday.

Plus Therapeutics Company Profile

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.